Vilanterol trifenatate

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314240

CAS#: 503070-58-4 (trifenatate)

Description: Vilanterol, also known as GW-642444, is a long-acting beta-2 agonist drug, which in May 2013 was approved in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).

Price and Availability

Size Price Shipping out time Quantity
10mg USD 150 Same day
25mg USD 250 Same day
50mg USD 450 Same day
100mg USD 650 Same day
200mg USD 950 Same day
500mg USD 1250 Same day
1g USD 1950 Same day
2g USD 2950 Same day
5g USD 4950 2 weeks
Inquire bulk and customized quantity

Pricing updated 2020-04-08. Prices are subject to change without notice.

Vilanterol trifenatate, purity > 98%, is in stock.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 314240
Name: Vilanterol trifenatate
CAS#: 503070-58-4 (trifenatate)
Chemical Formula: C44H49Cl2NO
Exact Mass: 485.17358
Molecular Weight: 774.776
Elemental Analysis: C, 68.21; H, 6.38; Cl, 9.15; N, 1.81; O, 14.45

Related CAS #: 503070-58-4 (trifenatate)   503068-34-6 (free base)    

Synonym: GW-642444; GW642444; GW-642444; GW 642444X; Vilanterol; Vilanterol trifenatate.

IUPAC/Chemical Name: (R)-4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol 2,2,2-triphenylacetate


InChi Code: InChI=1S/C24H33Cl2NO5.C20H16O2/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28;21-19(22)20(16-10-4-1-5-11-16,17-12-6-2-7-13-17)18-14-8-3-9-15-18/h5-9,14,24,27-30H,1-4,10-13,15-17H2;1-15H,(H,21,22)/t24-;/m0./s1


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (SDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO.

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Additional Information

Related CAS#
503070-58-4 ( Vilantero trifenatate);
503068-34-6 ( Vilantero free base)


1: Albertson TE, Richards JR, Zeki AA. The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience. Ther Adv Respir Dis. 2016 Feb;10(1):43-56. doi: 10.1177/1753465815619136. Epub 2015 Dec 14. Review. PubMed PMID: 26668137.

2: Wolthers OD. Pharmacokinetics and Systemic Activity of a New Patent of an Inhaled Corticosteroid/Long-Acting β2-Agonist Combination for Use in Asthma Therapy: Fluticasone Furoate/Vilanterol Trifenatate. Recent Pat Inflamm Allergy Drug Discov. 2015;9(2):144-50. PubMed PMID: 26581314.

3: Spyratos D, Sichletidis L. Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review. Ther Clin Risk Manag. 2015 Mar 25;11:481-7. doi: 10.2147/TCRM.S67491. eCollection 2015. Review. PubMed PMID: 25848294; PubMed Central PMCID: PMC4378877.

4: Albertson TE, Harper R, Murin S, Sandrock C. Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol. Patient Prefer Adherence. 2015 Feb 2;9:235-42. doi: 10.2147/PPA.S71535. eCollection 2015. Review. PubMed PMID: 25673975; PubMed Central PMCID: PMC4321647.

5: Relvar Ellipta for asthma. Drug Ther Bull. 2014 Aug;52(8):93-6. doi: 10.1136/dtb.2014.8.0273. Review. PubMed PMID: 25125553.

6: Hussar DA, Dharsi N. Umeclidinium bromide/vilanterol trifenatate, perampanel, and eslicarbazepine acetate. J Am Pharm Assoc (2003). 2014 Jul-Aug;54(4):450-2, 454-5. doi: 10.1331/JAPhA.2014.14527. PubMed PMID: 25063267.

7: Malerba M, Morjaria JB, Radaeli A. Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2014 Jun 27;9:687-95. doi: 10.2147/COPD.S47792. eCollection 2014. Review. PubMed PMID: 25061288; PubMed Central PMCID: PMC4085305.

8: Cada DJ, Ingram K, Leonard J, Baker DE. Umeclidinium bromide and vilanterol trifenatate inhalation powder. Hosp Pharm. 2014 Jun;49(6):554-62. doi: 10.1310/hpj4906-554. PubMed PMID: 24958974; PubMed Central PMCID: PMC4062736.

9: ▼Relvar Ellipta for COPD. Drug Ther Bull. 2014 Jun;52(6):66-9. doi: 10.1136/dtb.2014.6.0258. Epub 2014 Jun 5. PubMed PMID: 24904005.

10: Hussar DA, Ahmad A. Vilanterol trifenatate/fluticasone furoate, lomitapide mesylate, and mipomersen sodium. J Am Pharm Assoc (2003). 2013 Nov-Dec;53(6):662-70. doi: 10.1331/JAPhA.2013.13538. PubMed PMID: 24185435.

11: Agustí A, de Teresa L, De Backer W, Zvarich MT, Locantore N, Barnes N, Bourbeau J, Crim C. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Eur Respir J. 2014 Mar;43(3):763-72. doi: 10.1183/09031936.00054213. Epub 2013 Oct 10. PubMed PMID: 24114969.

12: Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013 Apr;26(2):256-64. doi: 10.1016/j.pupt.2012.12.001. Epub 2012 Dec 8. PubMed PMID: 23232038.

13: Slack RJ, Barrett VJ, Morrison VS, Sturton RG, Emmons AJ, Ford AJ, Knowles RG. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013 Jan;344(1):218-30. doi: 10.1124/jpet.112.198481. Epub 2012 Nov 6. PubMed PMID: 23131596.

14: Kempsford R, Allen A, Bal J, Rubin D, Tombs L. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects. Br J Clin Pharmacol. 2013 Jun;75(6):1478-87. doi: 10.1111/bcp.12019. PubMed PMID: 23116485; PubMed Central PMCID: PMC3690106.

15: Lötvall J, Bateman ED, Bleecker ER, Busse WW, Woodcock A, Follows R, Lim J, Stone S, Jacques L, Haumann B. 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. Eur Respir J. 2012 Sep;40(3):570-9. doi: 10.1183/09031936.00121411. Epub 2012 Feb 23. PubMed PMID: 22362859.

16: Busse WW, Bleecker ER, Bateman ED, Lötvall J, Forth R, Davis AM, Jacques L, Haumann B, Woodcock A. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax. 2012 Jan;67(1):35-41. doi: 10.1136/thoraxjnl-2011-200308. Epub 2011 Aug 9. PubMed PMID: 21828231.

17: Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010 Oct 29;11:149. doi: 10.1186/1465-9921-11-149. Review. PubMed PMID: 21034447; PubMed Central PMCID: PMC2991288.